Key Takeaways
- Volume up, revenue down: Sales volume grew 2% in Q2 but revenue fell 4% as realizations dropped across CPVC, hydrogen peroxide and caustic soda, while an extended monsoon and plant maintenance further capped output.
- Margins held at 25% in H1 despite low utilization: The 300 bps YoY H1 EBITDA margin decline to 25% came from lower realizations and under-absorption, not cost blowouts; Q2 alone slipped to 23% on inventory timing effects.
- Chlorotoluene is a cost centre today, a contributor tomorrow: The plant commissioned in March 2025 carried only expenses, depreciation and interest in H1; management expects sizable revenue to begin in Q4 FY26 or Q1 FY27.
- CPVC is at a cyclical bottom with a lagged recovery path: Prices fell because PVC raw material prices declined over the past year, and the pass-through lag means CPVC realizations should improve only from Q4 onwards once PVC recovers.
- What to watch next quarter: Whether CPVC and caustic soda realizations stabilize, the pace of Chlorotoluene revenue ramp-up, and the Board approval and announcement of the new chemistry CAPEX.
Top-Line & Volume Dynamics
- Volume grew but revenue shrank: Sales volume rose 2% in Q2 FY26 while revenue fell 4%, driven entirely by lower realizations in select product categories. The volume performance itself was constrained by an extended monsoon, subdued demand and plant maintenance work.
- H1 was weak on both counts: Both value and volume declined in H1 FY26. With the monsoon now concluded and plant maintenance completed, management sees early signs of demand recovery.
- CPVC price mechanics: CPVC prices move in tandem with PVC raw material prices with a lag of roughly one quarter. The PVC price decline that began last November fed through to CPVC with a four-to-five-month delay, and marginal PVC movements do not trigger CPVC price changes, only large ones do.
- Caustic soda added to the drag: Caustic soda realization dropped around 10% on a QoQ basis, compounding the CPVC and hydrogen peroxide price weakness.
- ECH bucked the trend: In Epichlorohydrin, glycerin prices moved up and that increase reflected in ECH prices, providing a partial offset.
Milind Kotecha: "See, generally the price of, as Maulik sir earlier said, PVC price increases, that impacts the CPVC price. And when the PVC price goes down, it also impacts the CPVC price. So, whatever price hike will come in the PVC, you should be able to pass on in the CPVC prices. But that happens with a lag of a quarter. So, that three to four months of lag will be there."
Margin Walk
- H1 margin held at 25% despite headwinds: EBITDA margin dropped from 28% in H1 FY25 to 25% in H1 FY26, majorly due to lower realizations for a few products and lower capacity utilization levels, not cost escalation.
- Q2 slipped further on inventory timing: Q2 EBITDA fell 19% to ₹132 CR and margins declined to 23% from 27% in Q1. The sequential drop came because prices corrected while the company held inventory purchased at higher prices, an effect management attributes partly to product mix.
- PAT tracked EBITDA: PAT dropped 36% YoY and PAT margin fell from 13% to 9%, purely because raw material prices for a few products inched up while realizations for CPVC, hydrogen peroxide and caustic soda went down.
- Utilization recovery is the margin lever: As plant utilization improves in H2, management expects further overall improvement in EBITDA margin, implying operating leverage is the primary path back to higher margins.
- Mark-to-market drag should reverse: The mark-to-market impact on derivatives is not an actual expense and is expected to turn around in coming quarters, though management cannot quantify exactly how much or when.
Chlorotoluene Value Chain
- Commissioned but not yet contributing: The Chlorotoluene plant was commissioned in March 2025. In H1 FY26, the P&L reflected only basic expenses, depreciation and interest cost with no contribution to top line or bottom line.
- Revenue timing is Q4 or Q1: Sizable revenue contribution should start from Q4 FY26 or Q1 FY27. Gradual incremental revenue will come in Q3 and Q4 but the base is very small and not a material amount to disclose. Once the plant is commissioned, it takes time to ramp up, and things should improve once it starts contributing, expected from Q1 FY27.
- First phase targets 8 to 9 products: The initial phase covers 8 to 9 products; a second phase may expand the portfolio further or add value-addition downstream. The value chain is expected to contribute sizable weight to the P&L from FY27 onwards.
- Management declined to break out product-wise revenue: When asked for revenue contribution from the CT chain, ECH and CPVC resins separately, management declined, stating only the broad split: 50% from chlor-alkali and 50% from derivatives and specialty business.
CPVC: Cycle, Capacity & Strategy
- The market is at the bottom: Management stated the current PVC and CPVC market is at the bottom. Volume should improve, and price should improve with a lag once PVC price improves, expected in Q3 or Q4 onwards.
- Resin is the backbone, not compound: The company is expanding only CPVC resin capacity because the resin plant is the capital-intensive, time-consuming backbone of the business. Compound capacity expansion, if needed, can be done in three months with limited CAPEX.
- Indian buyers are shifting to resin: Indian companies are increasingly buying resin only and expanding their own compound capacity, since compound expansion is not major CAPEX and the technology is accessible. This differs from the global pattern.
- Capacity doubling on track: The doubling of CPVC and Epichlorohydrin capacity, along with 19.8 MW wind-solar hybrid power plants, is moving as per schedule and expected to be commissioned within the timeline and budget announced.
Maulik Patel: "The resin plant, which is a backbone of the CPVC business, that is taking too much time to install as a CAPEX and install a capacity. And that is the major key drivers. And that is why we are announcing only the resin plant we are expanding."
Growth Projects & CAPEX
- New project at current complex: The company has moved a step closer to freezing a new project at its existing complex. Once Board approved, details will be announced. The project will strengthen the integrated complex and add to the value chain.
- New project at new land: A separate project on new land is at various stages of evaluation and should be frozen soon. It will be sizable enough to drive growth beyond FY2028, in line with the import substitution strategy where demand is expected to grow double-digit for a longer period with good ROCE.
- New chemistry CAPEX announcement this year: Management stated the new chemistry CAPEX will be announced mostly this year, once frozen and Board approved. The project targets growth beyond 2028: by the time CPVC and Epichlorohydrin run at optimum levels, the new project should start.
- New chemistry focus: The new product will target import substitution and products with double-digit growth for the next 10-15 years, in segments like construction and infrastructure where India's demand is structural and sustained.
- CAPEX horizon is 5 to 10 years: Management acknowledged that one year can have marginal or stagnant growth, but the CAPEX decision horizon is 5 to 10 years and eventually demand will absorb the supply coming.
Maulik Patel: "So, import substitute is a priority, but at the same time, we would like to target a product which is a growth for the next 10 years, which is in the construction or that kind of segment which India is going to have for the next 10-15 years if the continuous demand in terms of infrastructure is required as a country. So, we are targeting those kind of products which are having a double-digit growth for the next 10-15 years' time."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Volume growth | Volume should improve, with H2 FY26 stronger than H1 | Q3 FY26 onwards |
| EBITDA margin improvement | Further overall improvement expected as plant utilization improves in H2 | H2 FY26 |
| CPVC price recovery | CPVC prices expected to improve once PVC recovers, with a lag | Q4 FY26 onwards |
| Chlorotoluene revenue contribution | Sizable revenue contribution to begin | Q4 FY26 or Q1 FY27 |
| Chlorotoluene P&L weight | Value chain expected to contribute sizable weight to P&L | FY27 onwards |
| CPVC & ECH capacity doubling | Commissioning within timeline and budget announced | On schedule |
| New chemistry CAPEX announcement | CAPEX to be announced once frozen and Board approved | Mostly this year (FY26) |
| New project at new land | Sizable project to drive growth beyond FY2028; to be frozen soon | Beyond FY2028 |
| Full-year interest expense | Expected in the range of around ₹45 cr to ₹50 cr | FY26 |
| Derivative & specialty revenue share | Expect 70% revenue contribution from derivative and specialty business | Not dated |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue | ₹589 cr, down 4% YoY |
| H1 FY26 revenue | ₹1,204 cr, down ~6% YoY |
| EBITDA | ₹132 cr, down 19% YoY |
| EBITDA margin | ~23%, versus ~27% in Q1 FY26 |
| H1 FY26 EBITDA margin | 25%, versus 28% in H1 FY25 |
| Profit after tax | ₹51 cr, down 36% YoY |
| PAT margin | 9%, versus 13% in Q2 FY25 |
| Sales volume growth | 2% YoY |
| Plant utilization | 78%, versus 73% in Q1 FY26 and 83% in Q2 FY25 |
| CPVC capacity utilization | ~50%, similar to Q1 FY26 |
| CPVC price realization | ₹100–105 per kg, down from ~₹115 per kg previously |
| ROCE | 21% as on 30 Sep 2025, versus 23% as on 30 Sep 2024; ~24% excluding CWIP |
| Net debt to EBITDA | 0.8x as on 30 Sep 2025, versus 1.4x as on 30 Sep 2024 |
| Net debt | ₹496 cr as on 30 Sep 2025, versus ₹489 cr as on 31 Mar 2025 |
| CAPEX spent during H1 FY26 | ~₹236 cr |